.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD01_Palivizumab.Palivizumab

Information

Palivizumab is a humanized monoclonal antibody used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in high-risk pediatric patients, such as premature infants and those with certain heart or lung conditions. It is approved and used clinically for this preventative indication.

Pharmacokinetics

Population pharmacokinetic parameters in pediatric patients (including infants and children at high risk for RSV disease) following intravenous or intramuscular administration.

References

1. Zhu, Q, et al., & Suzich, JA (2017). A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Science translational medicine 9(388) –. DOI:10.1126/scitranslmed.aaj1928 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28469033

2. Simões, EAF, et al., & Villafana, T (2023). Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. The Lancet. Child & adolescent health 7(3) 180–189. DOI:10.1016/S2352-4642(22)00321-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36634694

3. Robbie, GJ, et al., & Roskos, LK (2012). Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrobial agents and chemotherapy 56(9) 4927–4936. DOI:10.1128/AAC.06446-11 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22802243

Revisions

• 06/2025 initial generated model